

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
14 August 2025 (14.08.2025)



(10) International Publication Number
WO 2025/171341 A3

(51) International Patent Classification:

A61P 3/00 (2006.01) C07D 519/00 (2006.01)
A61P 9/00 (2006.01) A61K 31/506 (2006.01)
A61P 19/08 (2006.01) A61K 31/437 (2006.01)
A61P 25/00 (2006.01) A61K 31/4375 (2006.01)
C07D 409/04 (2006.01) A61K 31/435 (2006.01)
C07D 471/04 (2006.01) A61K 31/4545 (2006.01)
C07D 491/048 (2006.01) A61K 31/4709 (2006.01)
C07D 495/04 (2006.01) A61K 31/4365 (2006.01)
C07D 498/04 (2006.01) A61K 31/538 (2006.01)

(21) International Application Number:

PCT/US2025/015123

(22) International Filing Date:

07 February 2025 (07.02.2025)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2024/076921
08 February 2024 (08.02.2024) CN
PCT/CN2024/097847
06 June 2024 (06.06.2024) CN
PCT/CN2024/132993
19 November 2024 (19.11.2024) CN
PCT/CN2024/141050
20 December 2024 (20.12.2024) CN

(71) Applicant: **ACONCAGUA BIO, INC.** [US/US]; 601 Gateway Blvd., Suite 900, South San Francisco, California 94080 (US).

(72) Inventors: **GAO, Zhenting**; c/o Aconcagua Bio, Inc., 601 Gateway Blvd., Suite 900, South San Francisco, California 94080 (US). **LEI, Hui**; c/o Aconcagua Bio, Inc., 601 Gateway Blvd., Suite 900, South San Francisco, California 94080 (US). **LI, Cui**; c/o Aconcagua Bio, Inc., 601 Gateway Blvd., Suite 900, South San Francisco, California 94080 (US). **LU, Chunliang**; c/o Aconcagua Bio, Inc., 601 Gateway Blvd., Suite 900, South San Francisco, California 94080 (US). **XUE, Ding**; c/o Aconcagua Bio, Inc., 601 Gateway Blvd., Suite 900, South San Francisco, California 94080 (US). **ZHANG, Haizhen**; c/o Aconcagua


Bio, Inc., 601 Gateway Blvd., Suite 900, South San Francisco, California 94080 (US). **ZHANG, Zhuming**; c/o Aconcagua Bio, Inc., 601 Gateway Blvd., Suite 900, South San Francisco, California 94080 (US). **HOUANG, Evelyn**; c/o Aconcagua Bio, Inc., 601 Gateway Blvd., Suite 900, South San Francisco, California 94080 (US). **LIU, Jian**; c/o Aconcagua Bio, Inc., 601 Gateway Blvd., Suite 900, South San Francisco, California 94080 (US). **NIE, Zhe**; c/o Aconcagua Bio, Inc., 601 Gateway Blvd., Suite 900, South San Francisco, California 94080 (US). **RU-VINSKY, Anatoly**; c/o Aconcagua Bio, Inc., 601 Gateway Blvd., Suite 900, South San Francisco, California 94080 (US). **THERRIEN, Eric**; c/o Aconcagua Bio, Inc., 601 Gateway Blvd., Suite 900, South San Francisco, California 94080 (US).

(74) Agent: **TANNER, Lorna L.** et al.; Sheppard Mullin Richter & Hampton LLP, 650 Town Center Drive, 10th Floor, Costa Mesa, California 92626-1993 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY



(57) Abstract: The present disclosure provides compounds of formula I for modulating calcitonin receptor and/or amylin receptor activity, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating a calcitonin receptor and/or amylin receptor associated disease or disorder.

[Continued on next page]

Declarations under Rule 4.17:

- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:

12 September 2025 (12.09.2025)